EUVIMEDEUVIMED entdecken
Open Access · CC BY-NC 4.0

Predictors of Super/Poor Omalizumab Response in Chinese Refractory Chronic Spontaneous Urticaria

Anqi Chen, Huan Yang, Xianjie Yang, Xuewei Huang, Shifei Li, Sisi Deng, Huan Wang, Zhiqiang Song, Qiquan Chen

Dermatology · 18.04.2026 · 242 (4) · 471-481

DOI: 10.1159/000551762 ↗

Kurz gefasst

Fachartikel in der Zeitschrift Dermatology, online erschienen am 18.04.2026. Verfasst von Anqi Chen und 8 weiteren Autor:innen. Beteiligte Einrichtung: Department of Dermatology, The First Affiliated Hospital (Southwest Hospital) of Army Medical University, Chongqing, China. Hauptthemen laut MEDLINE: Omalizumab, Chronic Urticaria, Anti-Allergic Agents. Die Arbeit wurde bisher 1-mal zitiert (Crossref) und nennt 35 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY-NC 4.0).

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Introduction

Omalizumab is an effective treatment for antihistamine-refractory chronic spontaneous urticaria (CSU), although treatment responses vary significantly. While fast and slow responders are well characterized, the profile of super responders (SRs) remains poorly understood. This study aimed to identify clinical and laboratory predictors of super response (SR) and poor/non-response (PR) to omalizumab in refractory CSU.

Methods

This retrospective study analyzed 307 CSU patients treated with omalizumab at a UCARE center between January 2023 and December 2024. SR was defined as achieving Urticaria Activity Score (UAS) = 0 within 1 week and sustained control (UAS7 ≤6, Urticaria Control Test [UCT] >12); PR was defined as UCT

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

OmalizumabChronic UrticariaAnti-Allergic AgentsHumansMaleFemaleRetrospective StudiesMiddle AgedAdultImmunoglobulin ETreatment OutcomeAgedChinaTreatment Effect HeterogeneityDrug ResistanceEast Asian People

Stichwörter der Autor:innen

Chronic spontaneous urticariaOmalizumabPoor responderPredictorsSuper responder

Substanzen

OmalizumabAnti-Allergic AgentsImmunoglobulin E

Autor:innen und Institutionen

  • Department of Dermatology, The First Affiliated Hospital (Southwest Hospital) of Army Medical University, Chongqing, China.
  • Chongqing Municipal Health Commission Key Laboratory of of Immunological Skin Diseases, Chongqing, China.
  • Institute of toxicology, school of preventive medicine, Army Medical University, Chongqing, China.
  • Department of Dermatology, The First Affiliated Hospital (Southwest Hospital) of Army Medical University, Chongqing, China, drsongzq@tmmu.edu.cn.
  • Chongqing Municipal Health Commission Key Laboratory of of Immunological Skin Diseases, Chongqing, China, drsongzq@tmmu.edu.cn.
  • Department of Dermatology, The First Affiliated Hospital (Southwest Hospital) of Army Medical University, Chongqing, China, chenqq0548@tmmu.edu.cn.

Zitieren

APA

Chen, A., Yang, H., Yang, X., Huang, X., Li, S., Deng, S., Wang, H., Song, Z., & Chen, Q. (2026). Predictors of Super/Poor Omalizumab Response in Chinese Refractory Chronic Spontaneous Urticaria. Dermatology, 242(4), 471-481. https://doi.org/10.1159/000551762

Vancouver

Chen A, Yang H, Yang X, Huang X, Li S, Deng S, et al. Predictors of Super/Poor Omalizumab Response in Chinese Refractory Chronic Spontaneous Urticaria. Dermatology. 2026;242(4):471-481. doi:10.1159/000551762

BibTeX
@article{Chen2026,
  author = {Chen, Anqi and Yang, Huan and Yang, Xianjie and Huang, Xuewei and Li, Shifei and Deng, Sisi and Wang, Huan and Song, Zhiqiang and Chen, Qiquan},
  title = {Predictors of Super/Poor Omalizumab Response in Chinese Refractory Chronic Spontaneous Urticaria},
  journal = {Dermatology},
  year = {2026},
  volume = {242},
  number = {4},
  pages = {471--481},
  doi = {10.1159/000551762}
}
Kostenlos starten →